Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.
The investment includes a new R&D center in Cambridge, Massachusetts, a manufacturing facility for biologics in Maryland and expanded capacities for the production of cell therapies on the West and East Coast as well as for the manufacture of specialty products in Texas.
Pascal Soriot, CEO of AstraZeneca, said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”
AstraZeneca said that the planned investments in the US are part of its ambition to achieve $80 billion in total revenue by 2030. According to AstraZeneca, the US is its largest market, generating 44% of total revenue.
Source: chemanager-online.com
Prange Pharma recently announced the successful completion of the acquisition of the MSD Animal Health manufacturing site in Aprilia, Italy. Following closing, the site will operate under the new name Aprilia Animal Health, establishing a dedicated European platform for contract manufacturing in the animal health sector.
Takeda has begun workforce reductions in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. The move marks the first disclosure of major job reductions after Takeda outlined the $1.26 billion, multiyear restructuring program to streamline operations and increase efficiency on March 25.
Evotec has appointed Ashiq Khan, Ph.D., as chief commercial officer, putting an executive with robotics and artificial intelligence experience in charge of a unit that is central to the company’s recently unveiled transformation plan.
